Atrial fibrillation in mainland China: epidemiology and current management

Zhang, Shu

doi:10.1136/hrt.2008.146589

Cited by 33 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study produced a crude AF prevalence rate of 0.77% and an age-adjusted rate of 0.61%, suggesting that approximately 8 million adults in China have AF [16,17]. AF is surely a substantial public health burden in China [18].…”

Section: Prevalence Of Cvd In Chinamentioning

confidence: 98%

Prevalence of cardiovascular diseases in China

Xiao

Chen

2010

Front. Med. China

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) cause one third of all deaths in China, and the number is anticipated to double by 2020. They also greatly result in disability and adjusted life year loss. The prevalence of CVD has become a new burden for China, due to an aging population, smoking, and changes in dietary habits and lifestyles. As the largest developing country, China needs to tailor her own national policies for managing CVD with full consideration of epidemiology, local needs, and affordability. Smoking cessation, increased physical activity, control of hypertension and hypercholesterolemia, and maintenance of a "traditional Chinese" diet should be important strategies for reducing the burden of CVD in China. Health officials in China should take their responsibilities to implement educational and preventive measures seriously.

show abstract

Section: Prevalence Of Cvd In Chinamentioning

confidence: 98%

Prevalence of cardiovascular diseases in China

Xiao

Chen

2010

Front. Med. China

View full text Add to dashboard Cite

show abstract

“…In contrast, a German AF registry—the Central Registry of German Competence Network on Atrial Fibrillation (AFNET)—demonstrated that only 21.3% of patients received antiarrhythmic medication, but 53.4% received electrical or pharmacologic cardioversion and 5% underwent AF ablation . Chinese data demonstrated variable use of rate‐control treatments, partly dependent on the AF phenotype . Among those with paroxysmal AF, 44% of patients received rate‐control treatment, compared to 83% of patients with permanent AF.…”

Section: Global Trends and Differences In Af Treatmentsmentioning

confidence: 99%

International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives

Hsu

Akao

Abe

et al. 2016

JAHA

View full text Add to dashboard Cite

“…Among multiple risk factors, age is a major contributor to the increase in AF prevalence . Epidemiological studies showed that over 1.83% of Chinese AF patients were older than 60 years, while 7.5% were older than 80 years . While life expectancy has been extended following the economic upturn in China, the increasing numbers of geriatric individuals, and those suffering from AF makes the management of AF a major public health concern.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of cryoballoon ablation for Chinese patients over 75 years old: A comparison with a younger cohort

Zhang

Ren

Wang

et al. 2019

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Introduction Cryoballoon ablation (CBA) results in satisfactory outcomes for drug‐resistant atrial fibrillation (AF) patients. However, the efficacy and safety of CBA have not yet been tested in the Chinese elderly population. Therefore, this study compared the recurrence of AF and complications of CBA in patients ≥75 years and <75 years. Methods A total of 677 patients (<75 years, n = 550; ≥ 75 years, n = 127) with paroxysmal (n = 603) or persistent (n = 74) non‐valvular drug‐resistant AF were included. The efficacy was assessed by the recurrence of AF, and the safety was evaluated by peri‐ and post‐procedural complications. Results The CHA2DS2‐VASc (2.6 ± 1.7 vs 4.8 ± 1.6, P < .01) and HAS‐BLED (1.8 ± 0.8 vs 2.0 ± 0.8, P = .01) scores were significantly higher in the elderly group. The instant pulmonary vein isolation success rate was comparable (99.11% younger vs 98.98% older, P = .99). After a mean follow‐up time of 12.8 ± 9.6 months, the 1‐year freedom from AF rate was 80.6% vs 85.8% in the older and younger groups, respectively, while the survival analysis showed a nonsignificant difference in the rate of freedom from AF (log‐rank P = .46). Cox regression showed that age was not a predictive factor for AF recurrence and was not dichotomized (hazard ratio [HR] = 0.868, 95% confidence interval [CI] 0.509‐1.481; P = .6046) or continuous (HR = 0.990, 95% CI, 0.968‐1.012, P = .3642). Similar complications rates were observed, including stroke (1.0% younger vs 0.93% older, P = .95) and major hemorrhagic events (1.2% younger vs 0% elder, P = .25). Conclusions The efficacy and safety profiles of CBA in patients older than 75 years are comparable with those in younger patients.

show abstract

Atrial fibrillation in mainland China: epidemiology and current management

Cited by 33 publications

References 21 publications

Prevalence of cardiovascular diseases in China

Prevalence of cardiovascular diseases in China

International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives

Efficacy and safety of cryoballoon ablation for Chinese patients over 75 years old: A comparison with a younger cohort

Contact Info

Product

Resources

About